These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Interleukin 1 receptor antagonist inhibits normal hematopoiesis and reduces lethality and bone marrow toxicity of 5-fluouracil in mouse.
    Author: Zhang J, Xiang D, Zhu S, Mao W, Lu H, Wu M, Wang Q, Yu Y, Herbst KD, Han W.
    Journal: Biomed Pharmacother; 2009 Aug; 63(7):501-8. PubMed ID: 18980827.
    Abstract:
    5-Fluouracil (5-Fu) targeting of cycling hematopoietic cells results in bone marrow (BM) suppression. Interleukin 1 receptor antagonist (IL-1Ra) is a cytokine that competitively blocks the binding of interleukin 1 (IL-1) to its receptor. Unlike the supporting role of IL-1 less is known for the role of IL-1Ra in hematopoiesis. Here, we demonstrate that IL-1Ra expression in BM cells and in circulation was elevated temporarily during 5-Fu-induced myelosuppression. Exogenous IL-1Ra administered to normal mice reversibly inhibited cycling status of BM cells, and reduced the numbers of BM cells including colony-forming progenitor cells, white blood cells (WBCs), and platelets in a dosage-dependent and time-dependent fashion. Due perhaps to its reversible suppression of the cell cycle progression of BM cells, pretreatment of normal mice with exogenous IL-1Ra reduced the acute lethal toxicity and BM suppression of 5-Fu, and accelerated the recoveries of BM cells and platelets following 5-Fu treatment. Pretreatment with IL-1Ra offers a new promising strategy to alleviate the BM toxicity of chemotherapy in clinical settings.
    [Abstract] [Full Text] [Related] [New Search]